Toby Maher
- Daily hand-held spirometry for the monitoring of patients with idiopathic pulmonary fibrosisBy Anne-Marie Russell, Pauline Lukey, Una Fraser, Elizabeth Renzoni, Athol Wells and Toby MaherAnne-Marie Russell1NIHR Biological Research Unit, Royal Brompton Hospital, London, United KingdomPauline Lukey3Fibrosis DPU, GSK, Stevenage, United KingdomUna Fraser1NIHR Biological Research Unit, Royal Brompton Hospital, London, United KingdomElizabeth RenzoniAthol Wells
- TGF-β 1 suppresses IRF-1 expression in pulmonary fibroblasts and modulates its induction by IFN α and IFN γBy Patricia Leoni, Xu Shi-Wen, Carmel Stock, David Abraham, Andrew Nicholson, Toby Maher, Athol Wells, Elizabeth Renzoni and Gisela LindahlPatricia Leoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomXu Shi-Wen2Department of Rheumatology, Royal Free Hospital, London, United KingdomCarmel Stock1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomDavid Abraham2Department of Rheumatology, Royal Free Hospital, London, United KingdomAndrew Nicholson3Department of Histopathology, Royal Bropmton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomElizabeth Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomGisela Lindahl1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- Pulmonary Langerhans' cell histiocytosis (PLCH): A new UK registerBy Rebecca Mason, Noeleen Foley, Howard Branley, Toby Maher, Martin Hetzel, Huzaifa Adamali and Jay SuntharalingamRebecca Mason1Respiratory Department, Musgrove Park Hospital, Taunton, Somerset, United KingdomNoeleen Foley2Respiratory Department, Royal United Hospital, Bath, Somerset, United KingdomHoward Branley5Respiratory Department, Whittington Hospital, London, United KingdomToby Maher4Respiratory Department, Royal Brompton, London, United KingdomMartin Hetzel3Respiratory Department, Bristol Royal Infirmary, Bristol, United KingdomHuzaifa Adamali4Respiratory Department, Royal Brompton, London, United KingdomJay Suntharalingam2Respiratory Department, Royal United Hospital, Bath, Somerset, United Kingdom
- Caspofungin to treat invasive pulmonary aspergillosis in sarcoidosisBy Benjamin Garfield, Greg Keir, Muhammad Anwar, Michael Loebinger, Robert Wilson, Elizabeth Renzoni, Athol Wells and Toby MaherBenjamin Garfield1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomGreg Keir1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomMuhammad Anwar1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomMichael Loebinger2Host Defense Unit, Royal Brompton Hospital, London, United KingdomRobert Wilson2Host Defense Unit, Royal Brompton Hospital, London, United KingdomElizabeth Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- Telomere (TL) shortening is associated with disease severity in scleroderma (SSC) associated interstitial lung disease (ILD)By Huzaifa I. Adamali, Cesar M. Delgado, Carmel Stock, Gisela E. Lindhal, Phil Molyneaux, Anne-Marie Russell, Athol Wells, Elizabeth A. Renzoni and Toby MaherHuzaifa I. Adamali1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomCesar M. Delgado1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomCarmel Stock1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomGisela E. Lindhal1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomPhil Molyneaux1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomAnne-Marie Russell1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomAthol Wells1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomElizabeth A. Renzoni1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United KingdomToby Maher1Interstitial Lung Disease, Royal Brompton Hospital and National Heart Lung Institute, Imperial College, London, United Kingdom
- Quality of life measures in patients with idiopathic pulmonary fibrosisBy Anne-Marie Russell, Una Fraser, Phil Molyneaux, Athol Wells, Elisabetta Renzoni, Pauline Lukey and Toby MaherAnne-Marie Russell1National Heart & Lung Institute, Imperial College, London, United KingdomUna Fraser2NIHR BRU, Royal Brompton Hospital, London, United KingdomPhil Molyneaux1National Heart & Lung Institute, Imperial College, London, United KingdomAthol Wells2NIHR BRU, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni2NIHR BRU, Royal Brompton Hospital, London, United KingdomPauline Lukey3Fibrosis DPU, Glaxo-Smith-Kline, Stevenage, United KingdomToby Maher2NIHR BRU, Royal Brompton Hospital, London, United Kingdom
- Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia: A randomized, double-blind, placebo-controlled studyBy Gregory Keir, Tamera Corte, Lisa Parfitt, Toby Maher, Phillip Marino, Elisabetta Renzoni, Konstantinos Dimopoulos, Michael Gatzoulis, Brendon Madden, Luke Howard, Paul Corris, Katherine O'Reilly, Ben Hope-Gill, Surinder Birring, Athol Wells and S. John WortGregory Keir1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomTamera Corte1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom3Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, AustraliaLisa Parfitt2National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomPhillip Marino2National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomKonstantinos Dimopoulos2National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United KingdomMichael Gatzoulis2National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United KingdomBrendon Madden4Respiratory Medicine, St Georges Hospital, London, United KingdomLuke Howard5Respiratory Medicine, Hammersmith Hospital, London, United KingdomPaul Corris6Cardio-Pulmonary Unit, The Freeman Hospital, Newcastle upon Tyne, United KingdomKatherine O'Reilly8Respiratory Medicine, Southampton General Hospital, Southampton, United KingdomBen Hope-Gill9Respiratory Medicine, Llandough Hospital, Cardiff, United KingdomSurinder Birring7Respiratory Medicine, Kings College Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomS. John Wort2National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United Kingdom
- Bromodomain inhibitor JQ1 attenuates TGF-β-suppressed SOD2 expression and reduces proliferation in human primary pulmonary fibroblastsBy Gisela Lindahl, Patricia Leoni, Carmel Stock, Charalambos Michaeloudes, Harpreet Lota, Andrew Nicholson, Toby Maher, Athol Wells, Ian Adcock and Elisabetta RenzoniGisela Lindahl1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomPatricia Leoni1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomCarmel Stock1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomCharalambos Michaeloudes2NHLI, Imperial College London, London, United KingdomHarpreet Lota1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomAndrew Nicholson3Histopathology, Royal Brompton Hospital, London, United KingdomToby Maher1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomAthol Wells1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United KingdomIan Adcock2NHLI, Imperial College London, London, United KingdomElisabetta Renzoni1ILDU/NHLI, Royal Brompton Hospital/Imperial College, London, United Kingdom
- Rituximab in severe, treatment-refractory interstitial lung diseaseBy Rezaur Abdullah, Damien Ming, Gregory Keir, Toby Maher, Athol Wells and Elisabetta RenzoniRezaur Abdullah1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomDamien Ming1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomGregory Keir1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- Scleroderma lung disease: Detection of pulmonary hypertension using pulmonary function tests is problematic in patients with emphysemaBy Katerina Antoniou, George Margaritopoulos, David Hansell, Sujal Desai, Toby Maher, Elizabeth Renzoni, Nikolaos Siafakas and Athol WellsKaterina Antoniou1Thoracic Medicine, Medical School, University of Crte, Heraklion, GreeceGeorge Margaritopoulos1Thoracic Medicine, Medical School, University of Crte, Heraklion, GreeceDavid Hansell2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomSujal Desai3Radiology, King's College, London, United KingdomToby Maher2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomElizabeth Renzoni2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomNikolaos Siafakas1Thoracic Medicine, Medical School, University of Crte, Heraklion, GreeceAthol Wells2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumoniaBy Gregory Keir, Tamera Corte, Konstantinos Dimopoulos, Michael Gatzoulis, Philip Marino, Elisabetta Renzoni, Toby Maher, Athol Wells and Stephen J. WortGregory Keir1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom2Respiratory Medicine Department, Princess Alexandra Hospital, Brisbane, AustraliaTamera Corte1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom3Rspiratory Medicine Department, Royal Prince Alfred Hospital, Sydney, AustraliaKonstantinos Dimopoulos4Pulmonary Hypertension Unit, Royal Brompton Hospital, London, United KingdomMichael Gatzoulis4Pulmonary Hypertension Unit, Royal Brompton Hospital, London, United KingdomPhilip Marino4Pulmonary Hypertension Unit, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomStephen J. Wort4Pulmonary Hypertension Unit, Royal Brompton Hospital, London, United Kingdom
- Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseasesBy Dina Visca, Angelo De Lauretis, Athol Wells, Andrew Montgomery, Toby Maher, Veronica Alfieri, Alfredo Antonio Chetta, Salvatore Valente and Elisabetta RenzoniDina Visca1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United Kingdom2Department of Respiratory Medicine, Ospedale Maggiore di Parma, Università degli Studi Di Parma, Parma, ItalyAngelo De Lauretis1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United Kingdom2Department of Respiratory Medicine, Ospedale Maggiore di Parma, Università degli Studi Di Parma, Parma, ItalyAthol Wells1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United KingdomAndrew Montgomery1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United KingdomToby Maher1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United KingdomVeronica Alfieri2Department of Respiratory Medicine, Ospedale Maggiore di Parma, Università degli Studi Di Parma, Parma, ItalyAlfredo Antonio Chetta2Department of Respiratory Medicine, Ospedale Maggiore di Parma, Università degli Studi Di Parma, Parma, ItalySalvatore Valente3Pulmonary Medicine Department, Ospedale Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, ItalyElisabetta Renzoni1Interstitial Lung Diseases, Royal Brompton Hospital, Imperial College, London, United Kingdom
- Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosisBy Vincent Cottin and Toby MaherVincent Cottin1National Reference Centre for Rare Pulmonary Diseases, Dept of Respiratory Medicine, Louis Pradel Hospital, Claude Bernard Lyon 1 University, UMR 754, Lyon, FranceToby Maher2National Heart and Lung Institute, Imperial College, London, UK3NIHR Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK
- Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptomsBy Angelo De Lauretis, Dina Visca, Simon Ward, Claudia Clayman, Charles Murray, Ong Voon, Christopher Denton, Gisela Lindahl, Carmel Stock, Alfredo Chetta, Marina Aiello, Veronica Alfieri, Michael Kreuter, Wim Wuyts, Toby Maher, Athol U. Wells and Elisabetta RenzoniAngelo De Lauretis1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom2Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyDina Visca1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom2Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalySimon Ward3Lung Function Department, Royal Brompton Hospital, London, United KingdomClaudia Clayman4Department of Gastroenterology, Royal Free Hospital, London, United KingdomCharles Murray4Department of Gastroenterology, Royal Free Hospital, London, United KingdomOng Voon5Deparment of Rheumatology, Royal Free Hospital, London, United KingdomChristopher Denton5Deparment of Rheumatology, Royal Free Hospital, London, United KingdomGisela Lindahl1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomCarmel Stock1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAlfredo Chetta2Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyMarina Aiello2Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyVeronica Alfieri2Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyMichael Kreuter6Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GermanyWim Wuyts7Laboratory of Pneumology, Dept. of Respiratory Medicine, Katholieke Universiteit Leuven and University Hospitals, Leuven, BelgiumToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol U. Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- A comparison of two scoring methods for the King's sarcoidosis questionnaireBy Aish Sinha, Sabrina Bajwah, Harry Gosker, Richard Siegert, Daniel Creamer, Genevieve Larkin, Toby Maher, Elisabetta Renzoni, Athol Wells, Irene Higginson, Surinder Birring and Amit PatelAish Sinha1Foundation Year Doctor, Buckinghamshire Healthcare Trust, High Wycombe, United KingdomSabrina Bajwah2, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London, London, United KingdomHarry Gosker3Department of Respiratory Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, NetherlandsRichard Siegert4Person Centred Research Centre, Health and Rehabilitation Research Institute, AUT University, Auckland, New ZealandDaniel Creamer5Department of Dermatology, King's College London, London, United KingdomGenevieve Larkin6Department of Ophthalmology, King's College London, London, United Arab EmiratesToby Maher7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomAthol Wells7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomIrene Higginson2, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London, London, United KingdomSurinder Birring8Division of Asthma, Allergy and Lung Biology, King's College London, London, United KingdomAmit Patel8Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom
- mTOR signalling is an essential pathway for TGF-β1 induced collagen synthesisBy Hannah Woodcock, Simon Peace, Carmel Nanthakumar, Toby Maher, Paul Mercer and Rachel ChamersHannah Woodcock1Centre for Inflammation and Tissue Repair, University College London, London, United KingdomSimon Peace2Fibrosis DPU, GSK Pharmaceuticals R&D Facility, Stevenage, United KingdomCarmel Nanthakumar2Fibrosis DPU, GSK Pharmaceuticals R&D Facility, Stevenage, United KingdomToby Maher1Centre for Inflammation and Tissue Repair, University College London, London, United KingdomPaul Mercer1Centre for Inflammation and Tissue Repair, University College London, London, United KingdomRachel Chamers1Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom
- A comparison of two scoring methods for the King's brief interstitial lung disease questionnaireBy Aish Sinha, Sabrina Bajwah, Harry Gosker, Richard Siegert, Daniel Creamer, Genevieve Larkin, Toby Maher, Elisabetta Renzoni, Athol Wells, Irene Higginson, Surinder Birring and Amit PatelAish Sinha1Foundation Year Doctor, Buckinghamshire Healthcare Trust, High Wycombe, United KingdomSabrina Bajwah2Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London, London, United KingdomHarry Gosker3Department of Respiratory Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, NetherlandsRichard Siegert4Person Centred Research Centre, Health and Rehabilitation Research Institute, AUT University, Auckland, New ZealandDaniel Creamer5Department of Dermatology, King's College London, London, United KingdomGenevieve Larkin6Department of Ophthalmology, King's College London, London, United KingdomToby Maher7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomAthol Wells7Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomIrene Higginson2Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London, London, United KingdomSurinder Birring8Division of Asthma, Allergy and Lung Biology, King's College London, London, United KingdomAmit Patel8Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom
- Response of the King's brief interstitial lung disease (KBILD) questionnaire to pulmonary rehabilitation (PR)By Claire M. Nolan, Jane L. Canavan, Sarah E. Jones, Samantha S.C. Kon, Faiza S. Chowdhury, Surinder S. Birring, Matthew Maddocks, Paul Cullinan, Toby Maher and William D.C. ManClaire M. Nolan1NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, Harefield, Middlesex United KingdomJane L. Canavan1NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, Harefield, Middlesex United KingdomSarah E. Jones1NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, Harefield, Middlesex United KingdomSamantha S.C. Kon1NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, Harefield, Middlesex United Kingdom2Respiratory Medicine, The Hillingdon Hospital NHS Foundation Trust, Uxbridge, Middlesex United KingdomFaiza S. Chowdhury3Collaboration for Leadership in Applied Health Research and Care North West London, Imperial College, London, United KingdomSurinder S. Birring4Division of Asthma, Allergy and Lung Biology, King's College London, London, United KingdomMatthew Maddocks5Cicely Saunders' Institute of Palliative Care and Research, King's College London, London, United KingdomPaul Cullinan6Faculty of Medicine National Heart and Lung Institute, Imperial College, London, United KingdomToby Maher7Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation Trust, London, United KingdomWilliam D.C. Man1NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, Harefield, Middlesex United Kingdom
- Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methodsBy Anne-Marie Russell, Tessa Sanderson, Sharon Fleming, Athol Wells, Toby Maher and Paul CullinanAnne-Marie Russell1Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute Imperial College, London, United Kingdom4Respiratory Biomedical Research Unit, Royal Brompton and Harefiled NHS Foundation Trust, London, United KingdomTessa Sanderson3Department of Anthropology, University of Durham, Durham, United KingdomSharon Fleming4Respiratory Biomedical Research Unit, Royal Brompton and Harefiled NHS Foundation Trust, London, United KingdomAthol Wells4Respiratory Biomedical Research Unit, Royal Brompton and Harefiled NHS Foundation Trust, London, United KingdomToby Maher2Leukocyte Biology, National Heart and Lung Institute Imperial College, London, United Kingdom4Respiratory Biomedical Research Unit, Royal Brompton and Harefiled NHS Foundation Trust, London, United KingdomPaul Cullinan1Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute Imperial College, London, United Kingdom4Respiratory Biomedical Research Unit, Royal Brompton and Harefiled NHS Foundation Trust, London, United Kingdom
- LSC Abstract – Changes in the respiratory microbiome during acute exacerbations of Idiopathic Pulmonary FibrosisBy Philip Molyneaux, William Cookson, Miriam Moffatt, Dong Soon Kim and Toby MaherPhilip Molyneaux1NHLI, Imperial College London, United KingdomWilliam Cookson1NHLI, Imperial College London, United KingdomMiriam Moffatt1NHLI, Imperial College London, United KingdomDong Soon Kim2Department of Pulmonary and Critical Care Medicine, University of Ulsan, South KoreaToby Maher1NHLI, Imperial College London, United Kingdom
- Optimal use of gas transfer values in detecting pulmonary vascular involvement in sarcoidosisBy Vasileios Kouranos, Simon Ward, Maria Kokosi, Joe Jacob, Diego Castillo, Felix Chua, Toby Maher, Andrew Nicholson, David Hansell, Elisabetta Renzoni and Athol WellsVasileios Kouranos1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomSimon Ward2Lung Function Department, Royal Brompton Hospital, London, United KingdomMaria Kokosi1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomJoe Jacob3CT Radiology Department, Royal Brompton Hospital, London, United KingdomDiego Castillo1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomFelix Chua1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomToby Maher1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAndrew Nicholson4Histopathology Department, Royal Brompton Hospital, London, United KingdomDavid Hansell3CT Radiology Department, Royal Brompton Hospital, London, United KingdomElisabetta Renzoni1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomAthol Wells1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.